LETTER TO THE EDITOR

Advances and effectiveness of the immunotherapy after liver transplantation

Sai Swarupa R Vulasala, Nirmal K Onteddu, Sindhu P Kumar, Chandana Lall, Priya Bhosale, Mayur K Virarkar

Sai Swarupa R Vulasala, Sindh P Kumar, Chandana Lall, Mayur K Virarkar, Department of Radiology, University of Florida College of Medicine, Jacksonville, FL 32209, United States

Nirmal K Onteddu, Department of Internal Medicine, Flowers Hospital, Dothan, AL 36305, United States

Priya Bhosale, Division of Diagnostic Imaging, Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States

Corresponding author: Sai Swarupa R Vulasala, MBBS, Research Assistant, Department of Radiology, University of Florida College of Medicine, 655 West 8th Street, C90, 2nd Floor, Clinical Center, Jacksonville, FL 32209, United States. vulasalaswarupa@gmail.com

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed

Peer-review model: Single blind

Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Chen YH, China; Koc OM, Belgium
A-Editor: Garg P, India

Received: November 23, 2021
Peer-review started: November 23, 2021
First decision: January 12, 2022
Revised: January 15, 2022
Accepted: June 13, 2022
Article in press: June 13, 2022
Published online: June 27, 2022

Abstract

Transplant recipients usually have increased chances of graft rejection and graft vs host disease, requiring chronic immunosuppressive therapy. Nonetheless, long-term immunosuppression risks malignancies such as skin cancer, lymphoma, and Kaposi sarcoma. However, there are very few studies that included solid organ transplant recipients while studying the efficacy of immunotherapy. “Immunotherapy after liver transplantation: Where are we now?” is a study, where the authors described the mechanism of action and outcomes of immune checkpoint inhibitors specific to liver transplant recipients. The authors reported the graft rejection rates and the factors contributing to the rejection in the liver transplant recipients.

Key Words: Immunotherapy; Hepatocellular carcinoma; Immune checkpoint inhibitors; Liver transplantation; Solid organ transplant; Graft rejection

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: There is an increased risk of cancer among transplant recipients receiving chronic immunosuppression. Immunotherapy has a beneficiary effect over immunosuppressors in reducing the overall cancer risk. However, there are very few studies that included solid organ transplant recipients while studying the efficacy of immunotherapy. “Immunotherapy after liver transplantation: Where are we now?” is a study, where the authors described the mechanism of action and outcomes of immune checkpoint inhibitors specific to liver transplant recipients.

Citation: Vulasala SSR, Onteddu NK, Kumar SP, Lall C, Bhosale P, Virarkar MK. Advances and effectiveness of the immunotherapy after liver transplantation. World J Gastrointest Surg 2022; 14(6): 629-631
URL: https://www.wjgnet.com/1948-9366/full/v14/i6/629.htm
DOI: https://dx.doi.org/10.4240/wjgs.v14.i6.629

TO THE EDITOR
Au et al[1] studied the consequences of immunotherapy in patients who underwent liver transplantation (LT) for hepatocellular carcinoma (HCC). We are writing to thank the authors after reading their article conscientiously. Many trials were conducted in the literature studying the efficacy of immunotherapy. However, they excluded organ transplant recipients due to the higher risk of fatal graft rejection. Transplant recipients usually have increased chances of graft rejection and graft vs host disease (GVHD), requiring chronic immunosuppressive therapy. Nonetheless, long-term immunosuppression risks malignancies such as skin cancer, lymphoma, and Kaposi sarcoma. These malignancies constitute the second most common cause of death in organ transplant recipients[2]. Immunotherapy is a breakthrough in managing transplant recipients and acts through interruption of the cancer-immunity cycle. Immune checkpoints, cytotoxic T-lymphocyte antigen 4 (CTLA-4), and programmed cell death 1 (PD-1) are physiologically responsible for preventing effector T cell overactivation.

Immunotherapy includes antibodies against CTLA-4 and PD-1, thereby upregulating the T-cell immune response to the cancer antigen[3]. Although the host immunity against tumor antigens is restored, on the other hand, T-cell stimulation is one of the significant components of graft rejection. The overall rejection rates following immunotherapy are 29%-54% and 25%, respectively, in patients who underwent solid organ transplantation and LT[4-6]. Kidney (40%) is associated with higher rates of graft rejection than liver (35%) and heart (20%)[3]. Au et al[1] studied that the graft rejection rates were seen in 32% of patients who specifically underwent an LT. The rejection rates among individuals who received immunotherapy within 2.9 years of transplant were increased compared to 5.3 years of transplant. They also noticed a higher mortality rate of 56% among graft rejected patients.

Compared with CTLA-4 inhibitors, PD-1 inhibitors are associated with higher rates of graft rejection and graft loss in LT recipients[7,8]. Kittai et al[9] reported graft rejection in 4 of 8 patients treated with anti-PD-1, whereas no rejections were detected in patients receiving anti-CTLA-4 therapy. Programmed death-ligand 1 (PD-L1) expression on the graft lymphocytes aids as a marker of rejection after immunotherapy[2]. Tacrolimus-based or combination agents (corticosteroids, antimetabolites, calcineurin inhibitors, and mechanistic target of rapamycin inhibitors) immunosuppression is shown to reduce graft rejection and improve the response to immunotherapy[2]. A 10%-20% of post-transplant patients encounter recurrence of HCC[10]. In such cases, immunotherapy is effective only in 11% of patients.

A higher dose of immunotherapy medication, a shorter interval between LT and immunotherapy initiation, expression of PD-L1 on the graft lymphocytes, and a previous GVHD history are positively related with the risk and response to graft rejection[4]. Studies on patient characteristics such as gender, age, pathological type of primary tumor, donor type, type, and duration of ischemia during LT and post-operative hepatitis virus status of the patient are necessary to learn the factors associated with favorable outcomes after immunotherapy. Proper patient selection is quintessential to preventing lethal graft rejection. Hence, a close collaboration among oncologists and transplant specialists is encouraged when handling patients who require immunotherapy. However, prospective studies focusing on: (1) Although the PD-1 pathway is dominant in establishing immune tolerance, whether anti-PD-1 and anti-CTLA-4 antibodies are associated with graft rejection[9]; (2) The treatment of immunotherapy related graft rejection; and (3) Its efficacy is there any difference in treatment modality between immunotherapy related graft rejection and isolated graft rejection, are required beforehand to recommend immune checkpoint inhibitors in transplant recipients.

FOOTNOTES

Author contributions: Vulasala SSR, Onteddu NK, Kumar SP, Lall C, Bhosale P, and Virarkar MK have equal contributions to this article.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: United States

ORCID number: Sai Swarupa R Vulasala 0000-0002-9387-3673; Nirmal K Onteddu 0000-0002-6267-0240; Sindhu P Kumar 0000-0002-3862-7453; Chandana Lall 0000-0002-5318-4160; Priya Bhosale 0000-0003-4014-4941; Mayur K Virarkar 0000-0002-5825-3102.

S-Editor: Wang JJ
L-Editor: A
P-Editor: Wang JJ

REFERENCES

1. Au KP, Chok KSH. Immunotherapy after liver transplantation: Where are we now? World J Gastrointest Surg 2021; 13: 1267-1278 [PMID: 34754394 DOI: 10.4240/wjgs.v13.i10.1267]

2. Kumar V, Shingare AB, Remnke HG, Ghai S, Lorch JH, Ott PA, Rahma OE. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. Oncologist 2020; 25: 505-514 [PMID: 32043699 DOI: 10.1634/theoncologist.2019-0659]

3. Fisher J, Zeitouni N, Fan W, Samie FH. Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review. J Am Acad Dermatol 2020; 82: 1490-1500 [PMID: 31302190 DOI: 10.1016/j.jaad.2019.07.005]

4. Hu B, Yang XB, Sang XT. Liver graft rejection following immune checkpoint inhibitors treatment: a review. Med Oncol 2019; 36: 94 [PMID: 31605245 DOI: 10.1007/s12032-019-1316-7]

5. Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M, Tariq MJ, Durer S, Russ A, Parr NNC, Baig Z, Sagar F, Ali Z, McBride A, Anwer F. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation. Biol Blood Marrow Transplant 2019; 25: 94-99 [PMID: 30195074 DOI: 10.1016/j.bbmt.2018.08.028]

6. Gassmann D, Weiler S, Mertens JC, Reiner CS, Vrugt N, Ngäeli M, Mangana J, Mullhaupt B, Jenni F, Misselwitz B. Liver Allograft Failure After Nivolumab Treatment-A Case Report With Systematic Literature Research. Transplant Direct 2018; 4: e376 [PMID: 30255136 DOI: 10.1097/TXD.0000000000000814]

7. Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Asciento PA, Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Liu F, McBride A, Anwer F. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation. Biol Blood Marrow Transplant 2019; 25: 94-99 [PMID: 30195074 DOI: 10.1016/j.bbmt.2018.08.028]

8. Wanchoo R, Riaella LV, Uppal NN, Lopez CA, Nair V, Devoe C, Jhaeveri KD. Immune checkpoint inhibitors in the cancer patient with an organ transplant. J Oncos-Nephrol 2017; 1: 42-48 [DOI: 10.5301/jon-n.5000106]

9. Kittai AS, Oldham H, Cetnar J, Taylor M. Immune Checkpoint Inhibitors in Organ Transplant Patients. J Immunother 2017; 40: 277-281 [PMID: 28719552 DOI: 10.1097/CJI.0000000000000180]

10. Johnston MP, Khakoo SI. Immunotherapy for hepatocellular carcinoma: Current and future. World J Gastroenterol 2019; 25: 2977-2989 [PMID: 31293335 DOI: 10.3748/wjg.v25.i24.2977]
